600062.SS Stock Analysis
60
Avoid
Based on Eyestock quantitative analysis, 600062.SS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
China Resources Double-Crane Pharmaceutical Co., Ltd. engages in the processing, manufacture, and sale of pharmaceutical, chemical, and biomedical raw materials. The company is headquartered in Beijing, Beijing and currently employs 11,029 full-time employees. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The firm's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The firm distributes its products mainly in domestic market.